KR20230151981A - 암 치료를 위한 병용 요법 - Google Patents

암 치료를 위한 병용 요법 Download PDF

Info

Publication number
KR20230151981A
KR20230151981A KR1020237023425A KR20237023425A KR20230151981A KR 20230151981 A KR20230151981 A KR 20230151981A KR 1020237023425 A KR1020237023425 A KR 1020237023425A KR 20237023425 A KR20237023425 A KR 20237023425A KR 20230151981 A KR20230151981 A KR 20230151981A
Authority
KR
South Korea
Prior art keywords
compound
formula
cancer
kras
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020237023425A
Other languages
English (en)
Korean (ko)
Inventor
리누스 마틴
레슬리 해리스 브레일
로버트 필드 슈메이커
Original Assignee
에라스카, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에라스카, 아이엔씨. filed Critical 에라스카, 아이엔씨.
Publication of KR20230151981A publication Critical patent/KR20230151981A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020237023425A 2020-12-11 2021-12-10 암 치료를 위한 병용 요법 Abandoned KR20230151981A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063124669P 2020-12-11 2020-12-11
US63/124,669 2020-12-11
US202163214736P 2021-06-24 2021-06-24
US63/214,736 2021-06-24
US202163277555P 2021-11-09 2021-11-09
US63/277,555 2021-11-09
US202163283035P 2021-11-24 2021-11-24
US63/283,035 2021-11-24
PCT/US2021/062927 WO2022125971A1 (en) 2020-12-11 2021-12-10 Combination therapies for the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20230151981A true KR20230151981A (ko) 2023-11-02

Family

ID=81974015

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237023425A Abandoned KR20230151981A (ko) 2020-12-11 2021-12-10 암 치료를 위한 병용 요법

Country Status (7)

Country Link
US (1) US20250195533A1 (https=)
EP (1) EP4259639A4 (https=)
JP (1) JP2023553534A (https=)
KR (1) KR20230151981A (https=)
AU (1) AU2021397319A1 (https=)
CA (1) CA3201612A1 (https=)
WO (1) WO2022125971A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
WO2023059771A1 (en) * 2021-10-06 2023-04-13 Erasca, Inc. Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
PL4426303T3 (pl) * 2021-11-02 2026-02-09 Semmelweis Egyetem Inhibitory transferazy farnezylowej i inhibitory kras do leczenia nowotworów z mutacją kras
PE20251110A1 (es) * 2022-08-19 2025-04-22 Mirati Therapeutics Inc Composiciones farmaceuticas solidas de adagrasib

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9670231B2 (en) * 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
EA201992781A1 (ru) * 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
JP7542538B2 (ja) * 2018-09-18 2024-08-30 ニカング セラピューティクス， インコーポレイテッド Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CN113164418A (zh) * 2018-12-05 2021-07-23 米拉蒂治疗股份有限公司 组合疗法
WO2020165732A1 (en) * 2019-02-12 2020-08-20 Novartis Ag Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
JP2023553533A (ja) * 2020-12-11 2023-12-21 エラスカ，インク． 癌の処置のための併用療法
JP2023553532A (ja) * 2020-12-11 2023-12-21 エラスカ，インク． 癌の処置のための併用療法
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer

Also Published As

Publication number Publication date
WO2022125971A1 (en) 2022-06-16
EP4259639A1 (en) 2023-10-18
JP2023553534A (ja) 2023-12-21
EP4259639A4 (en) 2024-10-23
AU2021397319A1 (en) 2023-07-27
AU2021397319A9 (en) 2024-05-16
CA3201612A1 (en) 2022-06-16
US20250195533A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
US20240293422A1 (en) Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
KR20230151981A (ko) 암 치료를 위한 병용 요법
JP6016825B2 (ja) 抗ｈｅｒ２抗体−薬剤コンジュゲートと化学療法剤の併用及び使用方法
US20170196878A1 (en) Use of cbp/ep300 and bet inhibitors for treatment of cancer
US11583577B2 (en) Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
KR20230154793A (ko) 암 치료를 위한 병용 요법
KR20230152652A (ko) 암 치료를 위한 병용 요법
CN111373055A (zh) 用于癌症的诊断和治疗方法
TW201938165A (zh) 治療癌症的方法及組合療法
TW202011991A (zh) 用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法
US20240285624A1 (en) Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy
CN117120449A (zh) 用于癌症治疗的联合疗法
WO2025226830A1 (en) Shp2 and egfr inhibitors for the treatment of chordoma
HK40103172A (zh) 用於癌症治疗的联合疗法
HK40103380A (zh) 用於癌症治疗的联合疗法
HK40103377A (zh) 用於癌症治疗的联合疗法
WO2023059771A1 (en) Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
CN117083283A (zh) 用于癌症治疗的联合疗法
CN117098537A (zh) 用于癌症治疗的联合疗法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1902 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1902 Submission of document of abandonment before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1902